May 04, 2021 03:20 PM IST
- May 04, 2021 03:03 PM IST
- Jan 29, 2021 09:11 AM IST
- Oct 29, 2020 09:44 AM IST
- Oct 27, 2020 06:33 PM IST
- Sep 18, 2020 10:46 PM IST
EQ India Fund acquired 8,88,888 shares in Gati (representing 0.7 percent of its total paid-up equity) at Rs 49.45 per share on the NSE. Katkar Sanjay bought 6,88,893 equity shares in Suven Life Sciences at Rs 56.27 per share.
- Aug 11, 2020 05:00 PM IST
- Feb 12, 2020 10:41 AM IST
According to its 2019 annual report, Suven Life Sciences posted total revenues of around Rs 688 crores and a net profit of around Rs 150 crores.
- Jan 21, 2020 04:10 PM IST
The record date for demerger is January 22, which means the person has to have Suven Life's shares in his/her account by end of this day and then he/she will be eligible for shares of CRAMs business.
- Jan 07, 2020 04:36 PM IST
The contract research and manufacturing services undertaking (including its respective assets and liabilities) of the company will be transferred to Suven Pharmaceuticals by way of demerger.
- Dec 02, 2019 11:05 AM IST
Considering the lower-than-anticipated R&D cost and operating expenses, we raise our FY20e and FY21e EBITDA respectively 16.7% and 22.8%.
- Dec 02, 2019 10:03 AM IST
The triple therapy of Masupirdine (SUVN-502) with Donepezil and Memantine proof of concept phase 2 study missed its pre-specified primary endpoint.
- Dec 01, 2019 08:57 AM IST
SUVN-502's clinical trial data assumed significance as no new Alzheimer's drug has been approved since Forest Labs' Namenda in 2003
- Nov 22, 2019 11:43 AM IST
The company says the phase 2 data for its SUVN 502, a drug for Alzheimer’s disease, will be out in a week.
- Nov 14, 2019 02:36 PM IST
Building material solutions provider HIL's Q2FY20 consolidated profit increased by 164 percent YoY to Rs 31.9 crore and revenue jumped 41.9 percent to Rs 585.9 crore compared to year-ago.
- Oct 17, 2019 09:48 AM IST
CRISIL assigned 'A' rating to company's long-term bank facilities and placed on ‘Rating Watch with Positive Implications'.
- Aug 26, 2019 12:32 PM IST
We raise our FY20 and FY21 estimates: of FY20 revenues 5 percent and FY21, 6 percent, and earnings 8 percent each, said research firm Anand Rathi.
- Jun 13, 2019 01:50 PM IST
Dolat Capital recommended Accumulate rating on Suven Life Sciences with a target price of Rs 310 in its research report dated May 28, 2019.
- May 27, 2019 12:57 PM IST
- Mar 29, 2019 11:33 AM IST
The granted claims of patents are being developed as therapeutic agents useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder, Huntington's disease, Parkinson's and schizophrenia, it added.
- Mar 08, 2019 10:55 AM IST
Suven Life Sciences through its joint venture partner, Shore Suven Pharma, Inc has entered into a "stalking-horse" asset purchase agreement to buy the assets of Aceto Corporation's Rising Pharmaceuticals and Rising subsidiaries, Suven Life said in a regulatory filing.
- Mar 08, 2019 09:40 AM IST
"This potential acquisition of Rising's assets would transform Shore Suven Pharma into a strong US generic pharmaceutical company," Venkat Jasti, CEO & Chairman of Suven Life Sciences said.
- Feb 06, 2019 10:55 AM IST
- Dec 27, 2018 11:29 AM IST
These two patents are valid through 2023 and 2034 respectively.
- Dec 27, 2018 10:59 AM IST
These patents are valid through 2023 and 2034, respectively, the company said in a BSE filing.